Marcus Schindler - Novo Nordisk Insider
| NVO Stock | USD 105.06 2.43 2.37% |
Insider
Marcus Schindler is Executive Vice President - Research and Early Development, Chief Scientific Officer of Novo Nordisk AS since 2021.
| Age | 58 |
| Tenure | 3 years |
| Address | Novo Alle 1, Bagsvaerd, Denmark, 2880 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has Return on Asset of 0.2147 % which means that on every $100 spent on assets, it made $0.2147 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8873 %, implying that it generated $0.8873 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Return On Capital Employed is likely to grow to 0.74, while Return On Assets are likely to drop 0.14. At this time, Novo Nordisk's Net Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.35, while Other Current Assets are likely to drop about 1.5 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kristen Ambrose | Vertex Pharmaceuticals | 47 | |
| Erin Burkhart | Biomarin Pharmaceutical | 45 | |
| Chad Cowan | Crispr Therapeutics AG | N/A | |
| Jennifer Doudna | Intellia Therapeutics | 60 | |
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| MBA MBA | Alnylam Pharmaceuticals | 59 | |
| Matthew MD | Crispr Therapeutics AG | 58 | |
| Reshma Shetty | Ginkgo Bioworks Holdings | 43 | |
| Mark Dmytruk | Ginkgo Bioworks Holdings | 53 | |
| Emmanuelle Charpentier | Crispr Therapeutics AG | N/A | |
| Rachel Haurwitz | Intellia Therapeutics | 38 | |
| CPA CPA | TG Therapeutics | 42 | |
| Lawrence Klein | Crispr Therapeutics AG | 42 | |
| Biegie Lee | Novavax | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| MBA MBA | Biomarin Pharmaceutical | 71 | |
| Marie Fallon | Ginkgo Bioworks Holdings | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Brendan MBA | Crispr Therapeutics AG | 48 | |
Management Performance
| Return On Equity | 0.89 | ||||
| Return On Asset | 0.21 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Doug Langa, Senior Vice President Head of North America Operations and Presidentident of Novo Nordisk Inc. | ||
| Kasim Kutay, Director | ||
| Sylvie Gregoire, Independent Director | ||
| Mette Jensen, Director, Employee Representative | ||
| Douglas Langa, Executive Vice President - North America Operations | ||
| Thomas Rantzau, Director, Employee Representative | ||
| Lars Jorgensen, CEO President | ||
| Daniel Bohsen, CVP Relations | ||
| Henrik Poulsen, Director | ||
| Karsten Knudsen, Chief Financial Officer, Executive Vice President | ||
| Lars Joergensen, President, Chief Executive Officer | ||
| Helge Lund, Independent Chairman of the Board | ||
| Martin Lange, Executive Vice President - Development | ||
| Maziar Doustdar, Executive Vice President - International Operations | ||
| Brian Daniels, Independent Director | ||
| Martin Mackay, Independent Director | ||
| Jeppe Christiansen, Vice Chairman of the Board | ||
| Anne Kverneland, Director, Employee Representative | ||
| Tania Sabroe, Executive Board | ||
| Liz Hewitt, Independent Director | ||
| Ludovic Helfgott, Executive Vice President of Biopharm | ||
| Camilla Sylvest, Executive Vice President - Commercial Strategy and Corporate Affairs | ||
| Mads Thomsen, Chief Science Officer, Executive VP and Member of Executive Management | ||
| Andreas Fibig, Independent Director | ||
| Monique Carter, Executive Vice President - People and Organisation | ||
| Laurence Debroux, Independent Director | ||
| Marcus Schindler, Executive Vice President - Research and Early Development, Chief Scientific Officer | ||
| Stig Stroebaek, Director, Employee Representative | ||
| Henrik Wulff, Executive Vice President - Product Supply Quality and IT |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.89 | ||||
| Return On Asset | 0.21 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.47 % | ||||
| Current Valuation | 465.74 B | ||||
| Shares Outstanding | 3.37 B | ||||
| Shares Owned By Institutions | 10.17 % | ||||
| Number Of Shares Shorted | 6.05 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 27.60 X |
Pair Trading with Novo Nordisk
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Moving together with Novo Stock
Moving against Novo Stock
| 0.92 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.86 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.86 | GILD | Gilead Sciences | PairCorr |
| 0.68 | KZR | Kezar Life Sciences | PairCorr |
| 0.6 | VRDN | Viridian Therapeutics | PairCorr |
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.